Oniani, David http://orcid.org/0000-0002-9221-3059
Hilsman, Jordan
Peng, Yifan http://orcid.org/0000-0001-9309-8331
Poropatich, Ronald K.
Pamplin, Jeremy C. http://orcid.org/0000-0003-3857-8417
Legault, Gary L. http://orcid.org/0000-0002-0878-1484
Wang, Yanshan http://orcid.org/0000-0003-4433-7839
Funding for this research was provided by:
Pitt | School of Health and Rehabilitation Sciences, University of Pittsburgh
U.S. Department of Health & Human Services | National Institutes of Health (R01LM014306)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (U24TR004111)
U.S. Department of Health & Human Services | National Institutes of Health (R01LM014306)
U.S. Department of Health & Human Services | National Institutes of Health (4R00LM013001)
National Science Foundation (2145640)
Article History
Received: 18 May 2023
Accepted: 15 November 2023
First Online: 2 December 2023
Competing interests
: Y.W. consults for Pfizer Inc. and has ownership/equity interests in BonafideNLP, LLC. All other authors declare no competing interests.